Sign in
Taking people in United StatesPhase 2

Tests CAR T cell therapy in young people with CD19-positive leukemia

Tests modified immune cells with chemotherapy in young people with relapsed leukemia.

Key facts

Who runs it
St. Jude Children's Research Hospital
Where
Memphis, United StatesSee the site
Trial code
Registry title
CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia
Status
Recruiting
Phase
Phase 2
People taking part
25 people, planned
Started
21 May 2025
Expected to end
Apr 2031
Type of study
Interventional
Treatments tested
  • Fludarabine
  • Cyclophosphamide
  • Mesna
  • CD19-CAR T cell Infusion
Record updated
25 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children, teenagers and young adults up to 21 years old whose CD19-positive leukemia did not respond to treatment or came back. They would get CAR T cell therapy.

Age
Up to 21 years old.
Sex
All sexes can join.
Disease stage
CD19-positive leukemia that does not respond to treatment, or has come back a 2nd or more times, or came back after a stem cell transplant from a donor. A 1st relapse can join if a donor transplant is needed but the person cannot have one. Disease must be detectable at treatment.
Earlier treatment
After a donor stem cell transplant, the person must be at least 3 months out, have no active graft-versus-host disease, and have had no donor lymphocyte infusion in the last 28 days.
Biomarker or test result
The leukemia must be confirmed CD19-positive within 3 months before enrollment.

Main reasons for not taking part

  • Known primary immunodeficiency
  • History of HIV infection
  • Active CNS-3 disease (leukemia in the central nervous system)
  • Severe, uncontrolled bacterial, viral or fungal infection
  • Allergic reaction in the past to products containing mouse protein

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • CD19+ leukemia** with any of the following:; Refractory disease (primary or in relapse); 2nd or greater relapse; Any relapse after allogeneic hematopoietic cell transplantation; 1st relapse if patient requires an allogeneic HCT as part of standard of care relapse therapy, but is found to be ineligible and/or unsuitable for HCT; must be confirmed to be CD19+ within 3 months prior to enrollment for treatment
  • Age: ≤ 21 years of age
  • Karnofsky or Lansky (age-dependent) performance score ≥ 50 (Appendix A)
  • Estimated life expectancy of > 12 weeks. Patients with a history of prior allogeneic hematopoietic cell transplantation [HCT] must be clinically recovered from prior HCT therapy, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to apheresis
  • For females of child bearing age:; Not lactating with intent to breastfeed; Not pregnant with negative serum pregnancy test within 7 days prior to enrollment
  • Age: ≤ 21 years of age
  • Estimated life expectancy of > 8 weeks
  • Detectable disease
  • Prior to planned CAR T cell infusion, patients with a history of prior allogeneic HCT must:; be at least 3 months from HCT; have no evidence of active GVHD; have not received a donor lymphocyte infusion (DLI) within the 28 days prior to planned infusion
  • Adequate cardiac function defined as left ventricular ejection fraction > 40%, or shortening fraction ≥ 25%
  • EKG without evidence of clinically significant arrhythmia
  • Adequate renal function defined as creatinine clearance or radioisotope GFR ³ 50 ml/min/1.73m2 (GFR ³ 40 ml/min/1.73m2 if < 2 years of age)
  • Adequate pulmonary function defined as forced vital capacity (FVC) ≥ 50% of predicted value; or pulse oximetry ≥ 92% on room air if patient is unable to perform pulmonary function testing
  • Karnofsky or Lansky (age-dependent) performance score ≥ 50 (Appendix A)
  • Total Bilirubin ≤ 3 times the upper limit of normal for age, except in subjects with Gilbert's syndrome
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal for age
  • Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy
  • For patients of child bearing age:; Not lactating with intent to breastfeed; Not pregnant with negative serum pregnancy test within 7 days prior to enrollment; If sexually active, agreement to use birth control until 6 months after T cell infusion

Who cannot take part

  • Known contraindication to receiving protocol defined lymphodepleting chemotherapy regimen; Treatment
  • Known contraindication to receiving protocol defined lymphodepleting chemotherapy regimen
  • History of HIV infection
  • Severe intercurrent bacterial, viral or fungal infection
  • History of hypersensitivity reactions to murine protein-containing products
  • Active CNS-3 disease
  • History of HIV infection
  • Evidence of active, uncontrolled neurologic disease
  • Severe, uncontrolled bacterial, viral or fungal infection
  • History of hypersensitivity reactions to murine protein-containing products
  • Known primary immunodeficiency
  • Known primary immunodeficiency

Other criteria

  • Autologous Apheresis and Manufacturing

Where in United States

  • St. Jude Children's Research HospitalMemphis, United StatesContact: Aimee Talleur, MDTaking people

About the trial

What the trial wants to find out

CAR19PK is a research study evaluating the use of lymphodepleting chemotherapy and chimeric antigen receptor (CAR) T cell therapy, a type of cellular therapy, for the treatment of refractory and/or relapsed leukemia. For this type of therapy, peripheral (circulating) immune cells are collected and then modified so that they can recognize an antigen, which is a particle present on the surface of a cancer cell. The CD19-CAR T cell product will be manufactured at the St. Jude Children's Research Hospital's Good Manufacturing Practice (GMP) facility.

Read full original descriptionShow less

The main purpose of this study is to determine:

* Evaluate different doses of fludarabine prior CAR T cell infusion * How your body processes fludarabine and cyclophosphamide, * How long the CAR T cells last in the body, * Whether or not treatment with this therapy is effective in treating people with refractory or relapsed leukemia, and * The side effects of this therapy.

The group in the trial

  • CAR19PK TherapyTreatment being tested

    This study contains two phases. Collection and Manufacturing Phase: Patient blood cells will be collected, and possibly frozen, via a process called apheresis. These cells will then be changed to improve their ability to recognize and kill cancer cells. Treatment Phase: Patients that meet eligibility for treatment will receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide, followed by an infusion of CD19-CAR T cells that were made in the Collection and Manufacturing Phase.

    Treatment: Fludarabine, Cyclophosphamide, Mesna, and CD19-CAR T cell Infusion

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia: An Investigation of Lymphodepleting Chemotherapy Pharmacokinetics
Plain-language title
Tests CAR T cell therapy in young people with CD19-positive leukemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
25 March 2026